Mereo BioPharma Group plc (MREO) News & Overview - Discounting Cash Flows
Mereo BioPharma Group plc
MREO (NASDAQ)
Open 2.76
Previous Close 2.76
Volume 819.9 Thou.
Average Volume 1.4 Mil.
Day's Range 2.76 โ€“ 2.94
52 Week Range 1.575-5.02
Market Cap 456.3 Mil.
Moving Average (50) 2.5318
Moving Average (200) 3.13203
Earnings per Share (EPS) -0.35
Price/Earnings (PE) -8.2
Shares Outstanding 159 Mil.
Earnings Date Aug 11, 2025
Beta 0.345
Last Dividend 0

MREO Latest News

MREO Business Model

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.

About Mereo BioPharma Group
Industry Biotechnology
Sector Healthcare
Number of Employees 36
Website & Executive
Website https://www.mereobiopharma.com
CEO (Chief Executive Officer) Denise Vera Scots-Knight
IPO date 2019-04-24
Contact
Country GB
Address One Cavendish Place
City London
State None
Phone 44 33 3023 7300
Zip Code W1G 0QF
Other Identifiers
CIK 0001719714
ISIN US5894921072
CUSIP 589492107
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us